For the past 20 years, the landscape of systemic treatments active against soft-tissue sarcoma (STS) has primarily consisted of conventional chemotherapy agents. To date, doxorubicin remains the standard first-line treatment for a vast majority of STS, while other agents such as ifosfamide, dacarbazine, gemcitabine, taxanes, trabectidin, and more recently eribulin are considered active in selected histological subtypes [1, 2].

...

The difficulties of demonstrating clinical activity for a new drug in this setting lies (i) in the heterogeneity of STS, a group of more than 50 different histological subtypes with different drug sensitivity profiles [1], and (ii) in the biological heterogeneity of tumors sharing identical morphological characteristics, but being different from a genetic point of view [3]. As...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.